Potentiation of motoneurone excitability by combined administration of 5-HT agonist and TRH analogue.
K A Clarke, A J Parker, G C Stirk
Neuropeptides June 1, 1985 DOI: 10.1016/0143-4179(85)90098-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats anaesthetised with urethane |
| Interventions | RX77368 5MeODMT |
| Dose | RX77368 1 mg/kg; 5MeODMT 0.4 mg/kg |
| Citations | 39 |
| Key findings | Combined administration of RX77368 and 5MeODMT potentiated the increase in amplitude and duration of motoneurone field potentials compared to either drug alone. |
Abstract
Motoneurone field potentials have been recorded from the lumbar region of the spinal cord, to antidromic stimulation of a ventral root, in rats anaesthetised with urethane. Injection of the thyrotropin releasing hormone (TRH) analogue RX77368 (1mg/kg) plus the 5-hydroxytryptamine (5-HT) receptor agonist 5-methoxy-N, N-dimethyl-tryptamine (5MeODMT 0.4mg/kg) resulted in a potentiation of the increase in amplitude and duration of response, compared to when the drugs were given singly. These results are discussed in the context of possible interactions between 5-HT and TRH systems.